What's next in nephrology — November 18, 2026
This issue covers six dated milestones between late November 2026 and the second quarter of 2027: two upcoming FDA target action dates (PDUFA) (povetacicept and imlifidase), a new PDUFA target date for a phosphate binder in dialysis, the World Congress of Nephrology, and two trial readouts with sponsor-estimated timing (inaxaplin in APOL1-mediated disease and the cell therapy rilparencel in advanced diabetic kidney disease).
1. Povetacicept in IgA nephropathy: FDA target action date
[Pending regulatory decision] [United States] [PDUFA target date: November 30, 2026, per Vertex]
What it is: An accelerated-approval application under priority review for povetacicept, a dual BAFF/APRIL inhibitor, 80 mg subcutaneously every four weeks, which has an FDA target action date (PDUFA) of November 30, 2026, per Vertex. It is based on the pre-specified 36-week interim analysis of RAINIER (NCT06564142; phase 3, randomized, double-blind, placebo-controlled, 605 adults randomized): in the 199 participants of the interim analysis (131 on povetacicept and 68 on placebo), proteinuria (24-hour UPCR) fell 52.0% from baseline with povetacicept, 49.8% versus placebo (p <0.001). On October 23, 2026 the results were published online in the New England Journal of Medicine and presented at ASN Kidney Week 2026; the confirmatory endpoint is total eGFR slope through week 104.
What problem it solves: Many patients with IgA nephropathy remain proteinuric despite RAS blockade, SGLT2 inhibitors and endothelin receptor antagonists; povetacicept targets production of galactose-deficient IgA1. It would be the second dual BAFF/APRIL inhibitor after atacicept's accelerated approval, announced on July 7, 2026.
Critical take: Approval would rest on a surrogate endpoint (proteinuria) measured in one third of participants; the two-year effect on filtration is not yet known and the trial is sponsor-run (Vertex). Regional applicability will depend on authorization, pricing and coverage.
Sources
- [Official release] Vertex Pharmaceuticals, June 1, 2026 (application acceptance and PDUFA date). https://news.vrtx.com/node/35066
- [Official release] Vertex Pharmaceuticals, March 9, 2026 (RAINIER interim results and use of a priority review voucher). https://www.businesswire.com/news/home/20260309179428/en/
- [Official release] Vertex Pharmaceuticals, November 2, 2026 (priority review and current PDUFA date). https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2026-financial-results
- [Article] N Engl J Med. 2026. DOI: 10.1056/NEJMoa2608682. https://doi.org/10.1056/NEJMoa2608682
- [Coverage] HCPLive, October 23, 2026. https://www.hcplive.com/view/rainier-povetacicept-cuts-proteinuria-gd-iga1-in-iga-nephropathy
- [Registry] NCT06564142, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06564142
- [Official release] Vera Therapeutics, July 7, 2026 (accelerated approval of atacicept). https://www.biospace.com/press-releases/vera-therapeutics-receives-fda-accelerated-approval-for-trutakna-for-adult-patients-with-primary-iga-nephropathy
2. Imlifidase to transplant highly sensitized candidates
[Pending regulatory decision] [United States] [PDUFA target date: December 19, 2026, per Hansa Biopharma]
What it is: According to Hansa Biopharma, the imlifidase application has an FDA target action date (PDUFA) of December 19, 2026; imlifidase is an IgG-cleaving enzyme that enables transplantation across a positive crossmatch. The pivotal ConfIdeS trial (NCT04935177; phase 3, open-label, randomized, 64 adults with cPRA ≥99.9% and a positive crossmatch against a deceased donor) showed mean 12-month eGFR of 51.5 versus 19.3 mL/min/1.73 m² in the control arm (p <0.0001), according to Hansa Biopharma.
What problem it solves: Highly sensitized patients may wait years or never receive a compatible kidney; off-label desensitization (IVIG, rituximab, plasmapheresis) has limited efficacy. It already holds conditional approval in the European Union.
Critical take: A small, open-label trial with a heterogeneous comparator (which included remaining on dialysis), favoring the eGFR difference; it requires round-the-clock immunology and monitoring for rebound antibody-mediated rejection.
Sources
- [Official release] Hansa Biopharma, March 4, 2026 (PDUFA date of December 19, 2026). https://www.inderes.fi/en/releases/hansa-biopharma-ab-pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026
- [Official release] Hansa Biopharma, September 24, 2025 (ConfIdeS results). https://tools.prnewswire.com/en-us/live/20823/release/20250924EN82516
- [Registry] NCT04935177, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04935177
3. Inaxaplin in APOL1-mediated kidney disease
[Ongoing trial] [International] [Estimated date: early 2027, per Vertex]
What it is: AMPLITUDE (NCT05312879) is a global phase 2/3 trial of oral inaxaplin 45 mg daily versus placebo on top of standard care in people with two APOL1 risk variants and severe proteinuria without another cause of kidney disease; with enrollment complete, Vertex stated in its November 2, 2026 report that it expects to share the interim analysis (when the cohort reaches 48 weeks) in early 2027, which could support accelerated approval. The final endpoint is eGFR slope at two years. On September 22, 2026, Vertex reported results from AMPLIFIED (phase 2b, open-label, single-arm, 41 people, 13 weeks): albuminuria (UACR) fell 42.7% in the modest-proteinuria cohort; in the type 2 diabetes cohort, the 17.3% reduction was inconclusive (95% CI: −36.3% to 7.2%).
What problem it solves: APOL1-mediated disease explains much of the excess kidney disease in people of sub-Saharan African ancestry and has no specific therapy: today only RAS blockade and general measures.
Critical take: The interim analysis will rest on a surrogate, not kidney events; Vertex sponsors it; it is highly relevant to populations of African descent such as much of the Caribbean, but requires APOL1 genotyping, which is scarce in the region.
Sources
- [Official release] Vertex Pharmaceuticals, November 2, 2026 (enrollment complete and interim analysis in early 2027). https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-third-quarter-2026-financial-results
- [Official release] Vertex Pharmaceuticals, September 22, 2026 (AMPLIFIED results). https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study
- [Coverage] HCPLive, September 23, 2026. https://www.hcplive.com/view/inaxaplin-cuts-proteinuria-in-broader-apol1-kidney-disease-population
- [Registry] NCT05312879, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05312879
4. Oxylanthanum carbonate for hyperphosphatemia on dialysis
[Pending regulatory decision] [United States] [PDUFA target date: March 25, 2027, per Unicycive]
What it is: Unicycive announced on October 21, 2026 that the FDA accepted its resubmission (Class II, six-month review) for oxylanthanum carbonate, with a target action date (PDUFA) of March 25, 2027, an oral nanoparticle phosphate binder filed via the 505(b)(2) pathway, for which it qualified because it contains a previously approved active moiety (lanthanum). According to the company, the June 2026 complete response letter cited deficiencies previously identified at the original third-party drug product manufacturer and raised no concerns about efficacy or safety data; the new filing adds a different manufacturer.
What problem it solves: Binder pill burden (sevelamer, calcium, lanthanum, ferric citrate, sucroferric oxyhydroxide) is a leading cause of poor adherence on dialysis; the company says its potency would allow fewer and smaller pills.
Critical take: It brings no new mechanism, and the adherence advantage is a company claim without published comparative outcome data. According to the company, the June letter focused on manufacturing; the application remains under review and the target date does not guarantee approval.
Sources
- [Official release] Unicycive Therapeutics, October 21, 2026. https://www.globenewswire.com/news-release/2026/10/21/3385397/0/en/unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-new-drug-application-resubmission-and-pdufa-date-of-march-25-2027.html
- [Official release] Unicycive Therapeutics, November 16, 2026 (current PDUFA date and reason for the June 2026 letter). https://www.globenewswire.com/news-release/2026/11/16/3403373/0/en/unicycive-therapeutics-announces-third-quarter-2026-financial-results-and-provides-business-update.html
5. World Congress of Nephrology 2027 (WCN'27)
[Congress] [Malaysia (Kuala Lumpur)] [Confirmed date: April 1, 2027 to April 4, 2027]
What it is: The annual congress of the International Society of Nephrology (ISN); abstract acceptance notifications are due December 8, 2026.
What problem it solves: It is an international forum with attention to low- and middle-income countries, relevant to practice in resource-limited settings.
Critical take: No late-breaking trials have been announced yet; its value will depend on the final program, which we will review in the next issue.
Sources
- [Meeting] International Society of Nephrology, WCN'27, official congress page (April 1 to 4, 2027, Kuala Lumpur). https://www.theisn.org/wcn/
- [Meeting] International Society of Nephrology, WCN'27, abstracts page (notification by December 8, 2026). https://www.theisn.org/wcn/abstracts/
6. Rilparencel (autologous cell therapy) in advanced diabetic kidney disease: PROACT 1
[Ongoing trial] [United States] [Estimated date: second quarter of 2027, per ProKidney]
What it is: PROACT 1 (NCT05099770) is a phase 3, 1:1 randomized, blinded trial of rilparencel (the patient's own kidney cells, reinjected percutaneously into each kidney) versus a sham procedure, with planned total enrollment of more than 500 adults with type 2 diabetes and stage 4 or late stage 3b CKD with albuminuria. ProKidney expects topline eGFR-slope results (efficacy analysis set of about 320 patients) in the second quarter of 2027 as the basis for accelerated approval; the composite endpoint (≥40% eGFR decline, eGFR <15, dialysis, transplant, or renal or cardiovascular death) is expected in the second half of 2029.
What problem it solves: In diabetic CKD with eGFR 20 to 35, the risk of reaching dialysis remains high despite SGLT2 inhibitors, finerenone and GLP-1 agonists; no therapy repairs kidney tissue.
Critical take: The first readout is a surrogate and the sponsor is ProKidney; it requires a kidney biopsy and individual manufacturing, limiting applicability in our setting even if positive.
Sources
- [Official release] ProKidney, November 12, 2026 (Exhibit 99.1 to Form 8-K filed with the SEC). https://www.sec.gov/Archives/edgar/data/0001850270/000119312526458470/prok-ex99_1.htm
- [Registry] NCT05099770, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05099770
Ready-to-paste WhatsApp text
*What's next in nephrology — November 18, 2026* 1. Povetacicept (IgA nephropathy): FDA PDUFA target action date: November 30, 2026. 2. Imlifidase (transplant in highly sensitized patients): FDA PDUFA target action date: December 19, 2026. 3. Inaxaplin (APOL1 kidney disease): AMPLITUDE interim analysis; estimated timing: early 2027, per Vertex. 4. Oxylanthanum carbonate (phosphate on dialysis): FDA PDUFA target action date: March 25, 2027. 5. World Congress of Nephrology, Kuala Lumpur: April 1–4, 2027. 6. Rilparencel (cell therapy in advanced diabetic CKD): PROACT 1 eGFR-slope results; estimated timing: Q2 2027, per ProKidney. Every item with an official source and a critical take. Full text and audio: https://boletinesmedicos.com/en/nephrology/2026-11-18-viene.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
What's next in nephrology (November 2026 – June 2027), with official target dates and sponsor-attributed estimates: • November 30: FDA PDUFA target date for povetacicept in IgA nephropathy (accelerated-approval application based on proteinuria). • December 19: FDA PDUFA target date for imlifidase to transplant highly sensitized patients. • Early 2027 (estimated timing, per Vertex): inaxaplin interim analysis in APOL1 kidney disease, relevant for populations of African descent. • March 25, 2027: FDA PDUFA target date for oxylanthanum carbonate for hyperphosphatemia on dialysis. • April 1–4, 2027: World Congress of Nephrology in Kuala Lumpur. • Second quarter of 2027 (estimated timing, per ProKidney): first PROACT 1 readout for the cell therapy rilparencel in advanced diabetic CKD. A PDUFA target date does not guarantee approval. Each item explains the clinical problem and gives an honest critical take. https://boletinesmedicos.com/en/nephrology/2026-11-18-viene.html #Nephrology #IgANephropathy #KidneyTransplant #Dialysis #CKD
Ready-to-paste X (Twitter) post
Nephrology: PDUFA targets for povetacicept 11/30, imlifidase 12/19, oxylanthanum carbonate 3/25/2027; WCN Apr 1–4, 2027. Estimated readouts: inaxaplin early 2027 (Vertex), PROACT 1 Q2 2027 (ProKidney). https://boletinesmedicos.com/en/nephrology/2026-11-18-viene.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.